What does BioCryst’s $700M Astria acquisition mean for the company?

BioCryst Pharmaceuticals' Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical drug that currently dominates the market, but with less burdensome dosing that could encourage HAE patients to switch.

Editor's Pick

Top Story BioCryst's $700M Astria Acquisition Gives It a Shot to Beat Larger Rivals in Rare Disease HAE BioCryst Pharmaceuticals' Astria Therapeutics acquisition brings navenibart, a drug in Phase 3 testing for the rare disease hereditary angioedema. The injectable antibody has the potential to match the efficacy of the blockbuster Takeda Pharmaceutical drug that currently dominates the market, but with less burdensome dosing that could encourage HAE patients to switch. Sponsored Boost Your Bottom Line and Employee Health Presented by Solera Health Facing rising healthcare costs and chronic conditions? You need a benefit strategy that delivers real ROI, not just a checklist. Watch our Solera Health webinar to learn how to: Quantify the ROI of digital health solutions billed as a medical benefit. Develop high-impact strategies that drive cost containment and improve employee outcomes for your workforce staff. Simplify vendor management and prepare your 2026 benefits plan. Register now to gain the insights and actionable steps needed to transform your benefits strategy!

Featured News

Ex-Cano Health CEO on Trial Amid $72M Fraud Claims Marlow Hernandez, the founder and former CEO of Cano Health, is facing a jury trial this week over allegations that he fraudulently enriched himself and his family while managing the senior-focused primary care company. Cano filed for bankruptcy last year — an event many industry experts attributed to Hernandez' poor governance. Withings Health Solutions Expands Obesity Care Network, Launches Best Practices for Treatment Programs Withings Health Solutions added Ilant Health to its Obesity Care Network and shared best practices to improve patient monitoring, engagement and outcomes. Stress Test: OBBBA, Rural Fragility, and Innovation Clinging to our old models is equivalent to waiting for failure. We need to embrace the tools, team structures, and delivery models that this ongoing crisis demands. IVF Coverage Proposals Could Squeeze U.S. Fertility Clinics Without Improving Access Ideas floated by the Trump Administration and Democrats in Congress aim to expand access to fertility treatment as an essential health benefit. But an influx of patients could collide with an already-brittle system of 430,000 annual cycles, 5,000 embryologists, and long-overdue lab upgrades.

Video   What Makes AI Startups Succeed in Healthcare To Chirag Shah, the success of a healthcare AI startup often depends on its ability to move beyond a narrow point solution. He believes it is essential to integrate AI into workflows and expand from initial "wedges" into full platforms.

Resources

MedCity Pivot Podcast: Price Transparency is the New North in the PBM World In this episode, a pharmacy benefit management executive and a pharmacy startup talk about why benefit verification, prior authorizations, and patient affordability still break the workflow and how smart integrations, real-time eligibility, and intuitive design can reduce friction for all involved. View Now

MedCity News • PO Box 901 • New York, NY unsubscribe